Treatment-Resistant Depression: Your Guide to Options Beyond Antidepressants

Most people don’t wake up one day and decide they have treatment-resistant depression.

Usually, it happens slowly.

A medication doesn’t help much.

Then another one doesn’t either.

Then life starts getting divided into strange little timelines based on prescriptions.

“That was during the Lexapro phase.”

“That was before we switched psychiatrists.”

“That was when I thought the dosage increase might finally help.”

People start remembering their lives that way after enough failed treatment attempts.

And honestly, that part can feel almost as draining as the depression itself.

If you are reading this because antidepressants haven’t worked for you — or for someone you love — this guide is for you. We will walk through what treatment-resistant depression actually is, why it happens, and most importantly, what genuine options exist in 2026 that go beyond another prescription change.

What Is Treatment-Resistant Depression?

Treatment-resistant depression means depression that keeps hanging around despite treatment. Not despite effort. That’s important.

A lot of patients dealing with TRD have actually been trying very hard for years — therapy appointments, medication adjustments, lifestyle changes, trying to stay hopeful long enough for the next thing to maybe work.

Approximately 1 in 3 people with major depression do not achieve adequate relief from standard antidepressant therapy.  — Rush et al., STAR*D Study, American Journal of Psychiatry

That is not a small or unusual group. It is a significant portion of everyone diagnosed with depression — and yet, treatment-resistant depression is chronically undertreated because the options available have historically been limited and difficult to access.

The Clinical Definition: What Does ‘Resistant’ Actually Mean?

Most psychiatrists consider depression treatment-resistant after two antidepressants have failed under proper treatment conditions — meaning adequate dosage, sufficient duration (typically at least six weeks each), and consistent use.

That sounds straightforward written down. In real life, it rarely feels straightforward. Because patients usually spend a long time wondering whether they’re somehow failing treatment personally before realising the treatment itself may not be working properly.

How Common Is Treatment-Resistant Depression?

More common than people think. Depression treatment gets discussed publicly as though antidepressants work cleanly for almost everybody if you just “find the right one.” But the clinical reality is often more uneven than that.

Some people improve quickly.

Some improve halfway.

Some feel emotionally stuck no matter what medication changes happen.

The STAR*D trial — the largest antidepressant effectiveness study ever conducted — found that after two failed antidepressant trials, the chances of achieving remission with a third medication drop to roughly 10 to 20 percent. That is why simply trying another antidepressant is not always the right answer.

Why Do Antidepressants Stop Working for Some People?

Nobody fully understands it yet. And patients can usually sense that uncertainty long before anybody says it directly. Sometimes antidepressants help briefly before symptoms return. Other times patients never feel substantial relief at all.

A lot of people eventually stop asking, “Why am I depressed?” and start asking, “Why does nothing seem to reach this?” That emotional shift changes people.

Part of the answer lies in the complexity of depression itself. The serotonin theory — which underpins most standard antidepressants — is real, but incomplete. Depression also involves the glutamate system, the stress response, neuroinflammation, and the brain’s capacity for neuroplasticity. SSRIs and SNRIs do not address all of these pathways, which is why they fall short for a meaningful proportion of patients.

The Emotional Reality of Living with TRD

One thing that happens quietly with treatment-resistant depression is that people become careful with hope. Not negative. Careful.

Family members say, “Maybe this new medication will finally help.” And the patient nods politely while internally trying not to believe too much in case this fails too. Again.

That emotional exhaustion is something we see regularly at Marpa Minds. Patients arrive having done everything right — followed every recommendation, tried every suggested medication — and still feel stuck. That experience is valid. And it is exactly why newer treatment pathways matter.

How Is Treatment-Resistant Depression Diagnosed?

There usually isn’t one dramatic test or moment. It’s more like looking back over years of treatment and noticing the pattern that’s already there.

The Two-Failure Rule Explained

In most cases, psychiatrists look for at least two antidepressants that failed despite adequate dosage, enough treatment time, and consistent use. Not every medication attempt counts equally — real treatment histories are messy, and a medication stopped after two weeks due to side effects may not meet the threshold.

The Massachusetts General Hospital Antidepressant Treatment Response Questionnaire (ATRQ) and the Maudsley Staging Method are tools some psychiatrists use to formally stage TRD severity — though in practice, many assessments remain conversational.

The Role of Adequate Dose and Duration

This gets oversimplified online constantly. Some medications are stopped too quickly because side effects become unbearable. Others never reach effective dosages. Sometimes patients are technically taking medication consistently but emotionally deteriorating the entire time.

Human treatment experiences don’t fit neatly into charts as often as people assume.

Ruling Out Other Contributing Factors

Before confirming a TRD diagnosis, a thorough psychiatrist will look at overlapping factors that may be driving depression resistance, including undiagnosed trauma or PTSD, burnout, anxiety disorders, sleep disorders, hormonal conditions such as hypothyroidism, chronic pain, substance use, and medication interactions.

Sometimes several things are happening at once and nobody slowed down enough earlier to fully untangle them. Addressing these contributors alongside the depression itself can sometimes change the treatment picture significantly.

Getting a Formal TRD Diagnosis: What to Expect

A proper psychiatric evaluation usually feels more conversational than people expect. Good psychiatrists often pay attention to things patients almost apologise for mentioning — patterns, timing, emotional flattening, the way someone talks about hope. That stuff matters.

If you have tried two or more antidepressants without adequate relief, it is reasonable to raise the possibility of a TRD evaluation directly with your psychiatrist. Many patients wait to be told rather than asking. You do not have to wait.

Why Standard Antidepressants Are Not Enough for Everyone

A lot of public conversation around antidepressants became very simplified over the years. Maybe too simplified.

The Serotonin Hypothesis: What It Gets Right and Wrong

SSRIs and SNRIs mainly focus on serotonin systems. And genuinely, they help many people. But depression clearly involves much larger brain systems too — stress response, trauma processing, neuroplasticity, glutamate activity. Human emotion is complicated. Brains are complicated. Psychiatry is still learning.

The 2022 Moncrieff et al. review in Molecular Psychiatry examined decades of serotonin research and found that the evidence for a direct link between serotonin deficiency and depression was weaker than widely assumed. This does not mean SSRIs do not work — they clearly do, for many people. It means the explanation for why they work is more complex than the simple “low serotonin = depression” model suggested.

 Why One in Three Patients Do Not Respond

Depression doesn’t even feel the same from person to person.

Some people feel crushing sadness.

Some feel numb.

Some feel mentally loud all day long.

Some barely feel connected to their own lives anymore.

Traditional antidepressants don’t always reach every version of depression equally well. Where serotonin-focused medications fall short, glutamate-targeting treatments like esketamine are showing genuine results — which is a large part of why Spravato® became such a significant development in psychiatric treatment.

The Risks of Indefinite Medication Cycling

After enough medication changes, some patients become emotionally detached from treatment altogether. That can scare families sometimes. But often it’s not apathy. It’s exhaustion.

There is also a practical concern beyond the emotional toll: each additional antidepressant trial carries its own side effect burden, taper schedule, and adjustment period. For patients who have been through multiple cycles, the cumulative disruption to work, relationships, and daily functioning can be significant. At some point, continuing to try medications that are unlikely to work is not neutral — it has a cost.

Modern Treatment Options for Treatment-Resistant Depression

Treatment-resistant depression does not automatically mean untreatable depression. That distinction matters more than people realise when they’re deep inside it.

Below are the main evidence-based options available in 2026 for patients whose depression has not responded to standard antidepressants.

Spravato® (Esketamine): The FDA-Approved First-Line Option for TRD

Spravato® became the first FDA-approved treatment specifically for treatment-resistant depression, cleared by the FDA in March 2019. Unlike traditional antidepressants, esketamine works through the glutamate NMDA receptor pathway — a fundamentally different mechanism that can produce rapid results where serotonin-targeting medications have failed.

Critically, Spravato® is covered by most major insurance plans — including Blue Cross Blue Shield, Aetna, UnitedHealthcare, and Cigna — making it financially accessible in a way that IV ketamine infusions typically are not.

Internal link: Anchor: ‘covered by most major insurance plans’ → /blog/is-spravato-covered-by-insurance

Ketamine Infusion Therapy

IV ketamine treatment has expanded rapidly over the last several years, partly because some patients experience relief much faster than they did with traditional antidepressants. And after years of waiting for medications to “eventually work,” speed starts mattering emotionally. Unlike Spravato®, IV ketamine is not FDA-approved for depression and is generally not covered by insurance, making it a self-pay option at most centres.

Internal link: Anchor: ‘IV ketamine’ → /blog/iv-ketamine-vs-spravato-nasal-spray

Transcranial Magnetic Stimulation (TMS)

TMS uses targeted magnetic pulses to stimulate areas of the brain associated with mood regulation, particularly the dorsolateral prefrontal cortex. A lot of patients value that it is non-invasive, does not involve sedation, and does not require adding another daily medication. TMS is FDA-cleared for treatment-resistant depression and is covered by many insurance plans after documented antidepressant failure.

Electroconvulsive Therapy (ECT): Modern ECT Is Not What You Think

ECT still carries heavy stigma from older media portrayals. Modern ECT is far more controlled, anaesthesia-assisted, and medically sophisticated than most people realise. Psychiatrists still consider it one of the most effective treatments available for severe or refractory depression, particularly where there is acute suicidal risk. It remains underused relative to its evidence base, largely due to stigma.

Psychotherapy Approaches That Help TRD

Therapy still matters deeply even when medications struggle — particularly approaches that address the patterns, beliefs, and nervous system responses that depression builds up over years. Evidence-supported approaches for TRD include Cognitive Behavioural Therapy (CBT), Acceptance and Commitment Therapy (ACT), and trauma-focused therapies such as EMDR. Many patients benefit from combining psychotherapy with biological treatments like Spravato® or TMS.

Emerging Treatments: Psilocybin, MDMA, and What’s Coming

Research around psychedelic therapy keeps growing. Psilocybin and MDMA are receiving enormous attention inside psychiatric research, and following President Trump’s April 2026 Executive Order to accelerate psychedelic medicine access, the timeline for broader availability may be shortening. Legally though, most remain limited to research settings for now.

What is available right now — legally, insurance-covered, and FDA-approved — is Spravato® (esketamine). It is classified as a dissociative psychedelic, making it the only legal psychedelic therapy accessible outside of a clinical trial in the United States today.

Internal link: Anchor: ‘the only legal psychedelic therapy accessible’ → /blog/psychedelic-therapy-what-it-is-how-it-works-legal

Spravato® for Treatment-Resistant Depression: A Closer Look

A lot of patients discover Spravato® surprisingly late — usually after years spent cycling through antidepressants that never fully helped. That realisation can bring frustration with it. Many tell us they wish someone had mentioned it years earlier.

“By the time most of our patients arrive at Marpa Minds, they have typically tried four, five, sometimes eight different medications. The thing that strikes me is not how unusual their situation is — it’s how common it is, and how long they’ve often had to wait before anyone offered them something genuinely different.”
— Amy Della Rocca, MSN, MPH, PMHNP-BC, Clinical Director, Marpa Minds

Why Spravato® Was Specifically Approved for TRD

Because psychiatry had to acknowledge something important: traditional antidepressants were not enough for a very large number of people. The FDA’s 2019 approval of esketamine was the first time a medication had ever been specifically approved for treatment-resistant depression — acknowledging TRD as a distinct clinical category requiring its own treatment pathway.

How It Works Differently from Every Previous Antidepressant

Esketamine targets the NMDA glutamate receptor — promoting rapid synaptogenesis (the growth of new synaptic connections) in brain regions associated with mood, emotional processing, and cognitive flexibility. This is a completely different pathway from every antidepressant approved before it.

The clinical effect of this different mechanism is speed. While SSRIs typically require four to eight weeks before meaningful improvement appears, clinical trials for esketamine reported significant antidepressant effects within two days of the first treatment.

In clinical trials, Spravato® demonstrated a statistically significant reduction in depression scores compared to placebo within 24 hours of the first dose.  — Daly et al., JAMA Psychiatry, 2018

Speed of Effect vs Traditional Antidepressants

One reason ketamine therapy gained so much attention is speed. Traditional antidepressants often take weeks before meaningful improvement appears. Some patients receiving ketamine-based treatment describe something different — not sudden happiness exactly. More like their thoughts finally becoming quieter for the first time in a long while.

For patients who have been waiting years for relief, that shift — even if partial at first — can change everything.

Finding Treatment-Resistant Depression Help at Marpa Minds

Marpa Minds is a certified Spravato® and ketamine therapy clinic in White Plains, NY, providing FDA-approved esketamine treatment for adults with treatment-resistant depression throughout Westchester County, Rockland County, and the New Jersey communities of Mahwah, Ramsey, Saddle River, and Bergen County.

The clinic focuses specifically on TRD care rather than broad general psychiatry. That matters because patients arriving here are often carrying years of failed treatment attempts, emotional burnout, and a very reasonable skepticism that anything new will actually help.

Which honestly makes sense.

By that stage, most people are not looking for exaggerated promises anymore. They just want something that finally feels possible.

Our clinical team — led by Amy Della Rocca, MSN, MPH, PMHNP-BC — handles the full treatment journey, from your initial eligibility assessment and insurance verification through every supervised Spravato® session. Most major insurance plans are accepted, including Blue Cross Blue Shield, Aetna, UnitedHealthcare, and Cigna. We manage all prior authorisation paperwork so you can focus on getting better.

If you are in Westchester County, Rockland County, or within 30 minutes of the New York–New Jersey border, a free consultation is the simplest next step. No obligation. Just a real conversation about what comes next.

Frequently Asked Questions About Treatment-Resistant Depression

Is treatment-resistant depression permanent?

No. Treatment-resistant depression is not permanent. Many people with TRD achieve significant improvement or full remission after finding the right treatment approach. Options like Spravato® (esketamine), ketamine therapy, and TMS have produced remission in patients who did not respond to multiple antidepressants. The key is accessing the right specialist and the right treatment pathway — not settling for another antidepressant trial.

What is the most effective treatment for treatment-resistant depression in 2026?

There is no single universal answer, because depression responds differently from person to person. However, in 2026, Spravato® (esketamine nasal spray) is the only FDA-approved medication specifically indicated for treatment-resistant depression. It is covered by most major insurance plans and has demonstrated rapid antidepressant effects in clinical trials. TMS, ketamine infusion therapy, ECT, and psychotherapy are also evidence-based options depending on individual circumstances.

How do I know if I have treatment-resistant depression?

The standard clinical definition is a diagnosis of major depressive disorder that has not responded adequately to at least two antidepressant medications taken at a therapeutic dose for a sufficient duration (typically six weeks or more). If this describes your experience, it is worth discussing a formal TRD evaluation with your psychiatrist — or seeking a second opinion from a TRD specialist.

Does insurance cover treatment for treatment-resistant depression?

It depends on the treatment. IV ketamine infusions are usually not covered by insurance and are typically self-pay. Spravato® (esketamine) is covered by most major commercial insurance plans including Blue Cross Blue Shield, Aetna, UnitedHealthcare, and Cigna, provided you meet the eligibility criteria. TMS is also covered by many plans after documented antidepressant failure. At Marpa Minds, we verify your insurance coverage before any treatment begins.

How is Spravato® different from other treatments for TRD?

Spravato® is the only FDA-approved medication specifically approved for treatment-resistant depression. It works through the glutamate NMDA receptor rather than the serotonin system, which is why it is effective in patients where SSRIs and SNRIs have failed. It is administered as a nasal spray in a certified medical clinic under supervision, typically twice weekly for four weeks in the initial phase. It is also covered by most major insurance plans, unlike IV ketamine.

Can treatment-resistant depression go into remission?

Yes, remission is possible. Clinical trial data for Spravato® shows significant response rates even in patients who have not responded to multiple prior medications. Remission timelines vary, and some patients require ongoing maintenance sessions, but a return to normal functioning is a realistic goal for many people with TRD.

What should I do if my psychiatrist says there is nothing else to try?

Get a second opinion. Psychiatry has changed significantly in the last five years, and a general psychiatrist may not be familiar with all current TRD-specific options including Spravato®, TMS, or ketamine-assisted therapy. A specialist in treatment-resistant depression — or a certified Spravato® clinic — can assess whether these options are appropriate for your situation.

Contact us to verify your insurance and book a free consultation.